ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Gleevec To Prevent Recurrence Of Gastrointestinal Cancer

December 26, 2008

Funding Opportunities: Department of Defense Ovarian Cancer Research

May 5, 2000

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990

NCI, Advisors Concur On Need For New Mechanism To Include Cancer Control, Minority Center Needs

September 21, 1984

Drug Company Cries Foul Over Clams Of Taxotere’s Superiority To Taxol

June 11, 1993

NCI Developing Plan To Replace Research Contracts At Academic Institutions With “Program Grants”

February 22, 1974